Improving the dose-myelotoxicity correlation in radiometabolic therapy of bone metastases with 153Sm-EDTMP. (Q50485352)

14 March 2018

title

Improving the dose-myelotoxicity correlation in radiometabolic therapy of bone metastases with 153Sm-EDTMP. (English)

1 reference

14 March 2018

author name string

Massimiliano Pacilio

1

1 reference

14 March 2018

Guido Ventroni

2

1 reference

14 March 2018

Chiara Basile

3

1 reference

14 March 2018

Pasquale Ialongo

4

1 reference

14 March 2018

Domenico Becci

5

1 reference

14 March 2018

Lucio Mango

6

1 reference

14 March 2018

publication date

1 February 2014

1 reference

14 March 2018

European Journal of Nuclear Medicine and Molecular Imaging

published in

1 reference

14 March 2018

volume

41

1 reference

14 March 2018

issue

2

1 reference

14 March 2018

page(s)

238-252

1 reference

14 March 2018

Bone metastasis. Prognosis, diagnosis and treatment

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2552-2

Clinical features of metastatic bone disease and risk of skeletal morbidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2552-2

Metastatic bone disease: clinical features, pathophysiology and treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2552-2

153Sm-EDTMP for bone pain palliation in skeletal metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2552-2

Radiopharmaceuticals for the palliation of painful bone metastasis-a systemic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2552-2

Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2552-2

Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2552-2

Combining 153Sm-lexidronam and docetaxel for the treatment of patients with hormone-refractory prostate cancer: first experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2552-2

Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2552-2

Gemcitabine radiosensitization after high-dose samarium for osteoblastic osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2552-2

High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2552-2

Dose-finding study of 153Sm-EDTMP in patients with poor-prognosis osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2552-2

Tandem dosing of samarium-153 ethylenediamine tetramethylene phosphoric acid with stem cell support for patients with high-risk osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2552-2

Tumor dosimetry and response for 153Sm-ethylenediamine tetramethylene phosphonic acid therapy of high-risk osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2552-2

A treatment planning method for sequentially combining radiopharmaceutical therapy and external radiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2552-2

A Phase I trial of samarium-153-lexidronam complex for treatment of clinically nonmetastatic high-risk prostate cancer: first report of a completed study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2552-2

Dosimetry and toxicity of Quadramet for bone marrow ablation in multiple myeloma and other haematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2552-2

A phase I study of samarium lexidronam/bortezomib combination therapy for the treatment of relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2552-2

Evaluation of methods for red marrow dosimetry based on patients undergoing radioimmunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2552-2

Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0),Tyr(3)]octreotate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2552-2

EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2552-2

Predicting hematologic toxicity in patients undergoing radioimmunotherapy with 90Y-ibritumomab tiuxetan or 131I-tositumomab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2552-2

Prospective dosimetry with 99mTc-MDP in metabolic radiotherapy of bone metastases with 153Sm-EDTMP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2552-2

Considerations of anthropometric, tissue volume, and tissue mass scaling for improved patient specificity of skeletal S values.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2552-2

Method for estimating skeletal spongiosa volume and active marrow mass in the adult male and adult female.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2552-2

Three methods assessing red marrow dosimetry in lymphoma patients treated with radioimmunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2552-2

Characterization of the [(153)Sm]Sm-EDTMP pharmacokinetics and estimation of radiation absorbed dose on an individual basis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2552-2

Lean body mass as a predictor of drug dosage. Implications for drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2552-2

Reevaluation of the standardized uptake value for FDG: variations with body weight and methods for correction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2552-2

Prediction of lean body mass from height and weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2552-2

An evaluation of R2 as an inadequate measure for nonlinear models in pharmacological and biochemical research: a Monte Carlo approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2552-2

Establishing a clinically meaningful predictive model of hematologic toxicity in nonmyeloablative targeted radiotherapy: practical aspects and limitations of red marrow dosimetry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2552-2

MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2552-2

High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2552-2

Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2552-2

A bone marrow toxicity model for ²²³Ra alpha-emitter radiopharmaceutical therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2552-2

Monte Carlo simulation of age-dependent radiation dose from alpha- and beta-emitting radionuclides to critical trabecular bone and bone marrow targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2552-2

Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting (90)Y-antibody therapy

21 January 2018

1 reference

12 December 2020

131I-labelled anti-CD22 MAb (LL2) in patients with B-cell lymphomas failing chemotherapy. Treatment outcome, haematological toxicity and bone marrow absorbed dose estimates

1 reference

12 December 2020

Correlation of red marrow radiation dosimetry with myelotoxicity: empirical factors influencing the radiation-induced myelotoxicity of radiolabeled antibodies, fragments and peptides in pre-clinical and clinical settings

1 reference

12 December 2020

Sensitivity of model-based calculations of red marrow dosimetry to changes in patient-specific parameters

1 reference

12 December 2020

Samarium-153-EDTMP biodistribution and dosimetry estimation

1 reference

12 December 2020

Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials

1 reference

12 December 2020

OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine

1 reference

12 December 2020

Bone destruction in cancer.

1 reference

12 December 2020

Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases

1 reference

12 December 2020

Human pharmacokinetics of samarium-153 EDTMP in metastatic cancer

1 reference

12 December 2020

Linear regression model for predicting patient-specific total skeletal spongiosa volume for use in molecular radiotherapy dosimetry.

1 reference

12 December 2020

Marrow toxicity and radiation absorbed dose estimates from rhenium-186-labeled monoclonal antibody.

1 reference

12 December 2020

EANM procedure guideline for treatment of refractory metastatic bone pain

1 reference

12 December 2020

Prediction of myelotoxicity using radiation doses to marrow from body, blood and marrow sources

1 reference

12 December 2020

Skeletal uptake and soft-tissue retention of 186Re-HEDP and 153Sm-EDTMP in patients with metastatic bone disease.

1 reference

12 December 2020

Imaging for improved prediction of myelotoxicity after radioimmunotherapy

1 reference

12 December 2020

Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial

1 reference

12 December 2020

Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison.

1 reference

12 December 2020

Hematologic toxicity in radioimmunotherapy: dose-response relationships for I-131 labeled antibody therapy

1 reference

12 December 2020

Analysis of multiple factors related to hematologic toxicity following 153Sm-EDTMP therapy

1 reference

12 December 2020

Comparison of methods for predicting myelotoxicity for non-marrow targeting I-131-antibody therapy

1 reference

12 December 2020

10.1007/S00259-013-2552-2

Identifiers

DOI

1 reference

14 March 2018

1 reference

14 March 2018